WebsiteGear Logo Log In
New User? Sign Up
About | Contact | FAQ
  Home News Web Hosting Domain Name Industry Wednesday, November 18, 2026 
Add Press Release News | News Feeds Feeds | Email This News Email


New Aetion Tool Brings Real-World Evidence Research to Small and Mid-Sized Pharma Companies
Friday, November 8, 2019

Bundled offering aims to advance regulatory-grade research capabilities for mid-market biopharma

NEW YORK, Nov. 1, 2019 /PRNewswire/ -- Today Aetion, the health care technology company that delivers real-world evidence for life sciences companies, payers, and regulatory agencies, announced a new integrated solution focused on advancing the use of real-world evidence for small and mid-sized biopharmaceutical companies. The new offering has been co-developed with IBM Watson Health as part of a strategic partnership announced at the 35th International Conference on Pharmacoepidemiology and Therapeutic Risk Management.

Aetion is offering components of the IBM MarketScan® Research Databases data, now embedded into its Aetion Evidence Platform®, to provide a turn-key solution for conducting regulatory-grade data analysis needed to unlock answers about the safety, effectiveness, and value of medical treatments. The combined IBM MarketScan Commercial and Medicare Supplemental Databases comprise one of the largest proprietary claims data sets available, which includes de-identified medical and drug claims; the MarketScan Lab Database includes lab results for a subset of individuals with claims.

This joint effort offers Aetion's customers a tool that can help them streamline the R&D process and address key questions in safety, medical affairs, and market access. The bundled product is designed to enable customers to conduct exploratory and descriptive analyses, including feasibility counts, prevalence and incidence, disease burden, population exploration, drug treatment pathways, hypothesis generation, comparative safety, and comparative effectiveness.

"Historically, substantial investment in real-world evidence has been almost the exclusive domain of large pharma," said Carolyn Magill, Aetion CEO. "By combining IBM Watson Health's data source and a best-in-class analytics platform in this bundled offering, innovative mid-market biopharma companies can now benefit from integrating real-world data into drug development and commercialization to help them solve data-driven challenges."

Real-world evidence studies enable researchers to supplement clinical trials by optimizing the development of treatments, determining new indications for drugs, and advancing regulatory approvals. Aetion is partnering with Brigham and Women's Hospital on the FDA demonstration project, RCT DUPLICATE, which will inform the agency's forthcoming guidance on the use of RWE for drug approvals.

Aetion customers can license the solution with a range of options -- from an entry-level bundle that includes access to insights from MarketScan data to 'a la carte' comparative and predictive analytics to all-inclusive bundled options.

About Aetion
Aetion is a health care technology company that delivers real-world evidence for life sciences companies, payers, at-risk providers, and regulatory agencies. The Aetion Evidence Platform® analyzes data from the real world to produce transparent, rapid, and scientifically validated answers on treatments, costs, and outcomes. Founded by Harvard Medical School faculty with decades of experience in epidemiology and health outcomes research, Aetion informs health care's most critical decisions -- what works best, for whom, and when -- to guide treatment development, commercialization, and payment innovation into health care's modern era.

Aetion is based in New York City, and backed by investors including New Enterprise Associates (NEA), Flare Capital Partners, Lakestar, Town Hall Ventures, McKesson Ventures, Sanofi Ventures, Amgen Ventures, UCB, and Horizon Health Services, Inc. Learn more at aetion.com, and follow us at @aetioninc.

View original content to download multimedia:http://www.prnewswire.com/news-releases/new-aetion-tool-brings-real-world-evidence-research-to-small-and-mid-sized-pharma-companies-300949716.html

SOURCE Aetion



Email This News Email | Submit To Slashdot Slashdot | Submit To Digg.com Digg | Submit To del.icio.us Del.icio.us | News Feeds Feeds

RELATED NEWS ARTICLES
Nav Skunk Works® and XTEND Expand Joint All Domain Command and Control for Advanced Mission Execution | Jan 22, 2026
Nav Sup AI Sets New Benchmark Record with 52.15% on Humanity's Last Exam | Jan 22, 2026
Nav Weekly Recap: 11 Tech Press Releases You Need to See | Jan 22, 2026
Nav Trigent Partners with WeWork India to Expand its GCC Footprint | Jan 22, 2026
Nav DEADLINE ANNOUNCED FOR 2026 NEW TOP-LEVEL DOMAIN APPLICATIONS | Jan 22, 2026
Nav Exia Labs Brings Keystone to the U.S. Navy via DIU's Blue Object Management Challenge | Jan 22, 2026
Nav Genpact Named a Leader in ISG Provider Lens(TM) 2025 for Insurance GCCs and Agentic AI Services | Jan 22, 2026
Nav Marketing Evolution Announces New Investment Led by Insight Partners to Power AI-Ready Marketing Data for the Agentic Era | Jan 22, 2026
Nav Glasswall Brings Defense-Level File Sanitization to Every Government Agency and Business Using Microsoft 365 | Jan 22, 2026
Nav Altair HyperWorks 2026 Delivers Design and Simulation at Scale with AI | Jan 22, 2026
NEWS SEARCH

FEATURED NEWS | POPULAR NEWS
Submit News | View More News View More News